|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer显示文摘Aim: To identify the metastasis suppressor genes for prostate cancer. Methods: A copy of human chromosomes was introduced into the highly metastatic Dunning R-3327 rat prostate cancer cells by the use of microcell-mediated chromosome transfer. Relationships between the size of human chromosomes introduced into microcell hybrid clones and the number of lung metastases produced by the clones were analyzed to determine which part of human chromosomes contained the metastasis suppressor gene (s) for prostate cancer. To determine portions of human chromosomes introduced, G-banding chromosomal analysis, fluorescence in situ hybridization analysis, and polymerase chain reaction analysis were performed. Results: Each of microcell hybrid clones containing human chromosomes 7, 8, 10, 11, 12, or 17 showed decreased ability to metastasize to the lung without any loss of ttmaorigenicity. This demonstrates that these human chromosomes contain metastasis suppressor genes for prostate cancer. Spontaneous deletion of portions of human chromosomes was observed in the human chromosome 7, 10, 11, 12, and 17 studies. In the human chromosome 8 study, irradiated microcell-mediated chromosome transfer was performed to enrich chromosomal ann deletions of human chromosome 8. Molecular and cytogenetic analyses of microcell hybrid clones demonstrated that metastasis suppressor genes on human chromosomes were located on 7q21-22, 7q31.2-32, 8p21-12, 10q11-22, 11p13-11.2, 12p11-q13, 12q24-ter, and 17pter-q23. KAI1 and MKK4/SEKI were identified as metastasis suppressor genes from 11p11.2 and 17p12, respectively. Conclusion: This assay system is useful to identify metastasis suppressor gene (s) for prostate cancer. | Tomohiko ICHIKAWA Shigeru HOSOKI Hiroyoshi SUZUKI Koichiro AKAKURA Tatsuo IGARASHI Yuzo FURUYA Mitsuo OSHIMURA Carrie W.RINKER-SCHAEFFER Naoki NIHEI J.Carl BARRETT John T.ISAACS Haruo ITO | 2000 | Asian Journal of Andrology2000，2，3： | 2 |
| 2 | A model for ferrous-promoted chaleopyrite leaehing 显示文摘 | Naoki Hiroyoshi Hajime Miki Tsuyoshi Hirajima | 2000 | Hydrometallurgy2000，57，： | 1 |
| 3 | A case of ferrous sulfate addition enhancing chalcopyrite leaching 显示文摘 | Naoki Hiroyoshi Masahiko Hirota Tsuyoshi Hirajima | 1997 | Hydrometallurgy1997，47，： | 1 |
| 4 | Enhancement of chalcopyrite leaching by ferrous ions in acidicferric sulfate solutions显示文摘 | Hajime Miki Tsuyoshi Hirajima | 2001 | Hydrometallurgy2001，60，： | 1 |
| 5 | A new reaction model for the catalytic effect of silver ions on chalcopyrite leaching in sulfuric acid solutions显示文摘 | Masatoshi Arai Hajime Miki | 2002 | Hydrometallurgy2002，63，： | 1 |
| 6 | A Model for Ferrous-promoted ChaIcopyrite Leaehing显示文摘 | Naoki Hiroyoshi Hajime Miki Tsuyoshi Hirajima | 2000 | Hydrometallurgy2000，57，1： | 1 |
| 7 | Health‐related quality of life after carbon‐ion radiotherapy for prostate cancer: A 3‐year prospective study显示文摘 | Hiroyuki Katoh Hiroshi Tsuji Hitoshi Ishikawa Tadashi Kamada Masaru Wakatsuki Naoki Hirasawa Hiroyoshi Suzuki Koichiro Akakura Takashi Nakano Jun Shimazaki Hirohiko Tsujii | 2014 | Int J Urol2014，，： | 1 |
| 8 | Carrier-microencapsulation for preventing pyrite oxidation显示文摘 | Jacqueline Satur Naoki Hiroyoshi Masami Tsunekawa | 2007 | Int JMiner Process2007，83，： | 1 |
| 9 | Enhancement of chalcopyrite leaching by ferrous ions in acidic ferric sulfate solution显示文摘 | Naoki Hiroyoshi Hajime Miki Tsuyoshi Hirajima | 2001 | Hydrometallurgy2001，60，： | 1 |
| 10 | Perfusion CT is superior to angiography in predicting pancreatic necrosis in patients with severe acute pancreatitis显示文摘 | Yoshihisa Tsuji Kyoko Hamaguchi Yuji Watanabe Akira Okumura Hiroyoshi Isoda Naoki Yamamoto Osamu Kikuchi Hiroyuki Yamamoto Kazuhiro Matsueda Kenji Ueno Shinsuke Tada Kaori Togashi Hiroshi Yamamoto Tsutomu Chiba | 2010 | Journal of Gastroenterology2010，，11： | 1 |
| 11 | A case of ferrous sulfate addition enhancing chalcopyrite leaching显示文摘 | Naoki Hiroyoshi Masahiko Hirota Tsuyoshi Hirajima Masami Tsunekawa | 1997 | Hydrometallurgy1997，，1： | 1 |
| 12 | Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer显示文摘 | Hitoshi Ishikawa Hiroshi Tsuji Tadashi Kamada Naoki Hirasawa Takeshi Yanagi Jun-Etsu Mizoe Koichiro Akakura Hiroyoshi Suzuki Jun Shimazaki Hirohiko Tsujii | 2006 | International Journal of Radiation Oncology Biology Physics2006，，4： | 1 |
| 13 | Enhancement of chalcopyrite leaching by ferrous ions in acidic ferric sulfate solution显示文摘 | Naoki Hiroyoshi Hajime Miki Tsuyoshi Hirajima | 2001 | Hydrometallurgy2001，60，： | 1 |
| 14 | A new reaction model for the catalytic effect of silver ions on chalcopyrite leaching in sulfuric acid solutions 显示文摘 | Naoki Hiroyoshi Masatoshi Arai Hajime Miki | 2002 | Hydrometallurgy2002，63，： | 1 |
| 15 | A Consensus consensus linkage map for Sugi(Cryptomeria japonica)from two pedigrees, based on microsatellites and expressed sequence tags显示文摘 | Naoki Tani Tomokazu Takahashi Hiroyoshi Iwata | 2003 | Genetics2003，165，： | 1 |
| 16 | Clinical Significance of Computed Tomographic Assessment and Anatomic Features of the Inferior Alveolar Canal as Risk Factors for Injury of the Inferior Alveolar Nerve at Third Molar Surgery显示文摘 | Megumi Ueda Kenji Nakamori Kaori Shiratori Tomohiro Igarashi Takanori Sasaki Naoki Anbo Takeshi Kaneko Naohiro Suzuki Hironari Dehari Tomoko Sonoda Hiroyoshi Hiratsuka | 2012 | Journal of Oral and Maxillofacial Surgery2012，，3： | 1 |
| 17 | High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma显示文摘 | Takanobu Utsumi Koji Kawamura Takashi Imamoto Naoto Kamiya Akira Komiya Sawako Suzuki Hidekazu Nagano Tomoaki Tanaka Naoki Nihei Yukio Naya Hiroyoshi Suzuki Ichiro Tatsuno Tomohiko Ichikawa | 2012 | Surgery2012，，3： | 1 |
| 18 | Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over显示文摘BACKGROUND Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus,patients≥75-years-old have not been included in previous clinical trials.AIM To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients(≥75-years-old)compared to nonelderly patients,we conducted a post-marketing prospective cohort study.METHODS We treated 265 patients with genotype 2 hepatitis C virus using standard approved doses of sofosbuvir(400 mg/d)plus ribavirin adjusted by body weight,administered orally for 12 wk.RESULTS Sustained virological response rates for the overall cohort,patients<65-years-old,≥65-years-old but<75-years-old,and≥75-years-old were 97%(258/265),98%(93/95),97%(84/87),and 98%(81/83),respectively(P=0.842).Logistic regression analyses identified history of hepatocellular carcinoma treatment and alpha-fetoprotein as factors significantly associated with sustained virological response.Alpha-fetoprotein was the only independent factor identified.Sustained virological response rate was significantly lower for patients with hepatocellular carcinoma treatment(91%)than for patients without history of hepatocellular carcinoma treatment(98%,P=0.004).One patient(0.4%)discontinued treatment due to drug-induced pneumonia.Dose reduction or interruption of ribavirin was required for 12.1%(32/265)of patients because of anemia,including 7.7%(14/182)of patients<75-years-old and 21.7%(18/83)of patients≥75-years-old(P=0.002).CONCLUSION Although ribavirin dose reduction or interruption was required with advanced age,sofosbuvir plus ribavirin appears tolerable and highly effective even in patients≥75-years-old. | Hideyuki Tamai Naoki Shingaki Yoshiyuki Ida Ryo Shimizu Shuya Maeshima Junpei Okamura Akira Kawashima Taisei Nakao Takeshi Hara Hiroyoshi Matsutani Izumi Nishikawa Katsuhiko Higashi | 2020 | World Journal of Hepatology2020，12，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员